Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Osteopore Ltd. ( (AU:OSX) ) has provided an announcement.
Osteopore Limited has signed a multi-year, exclusive distribution agreement worth more than RMB 12 million with Majeton Pte Ltd to commercialise its dental, orthodontic and maxillofacial products in China, Hong Kong and Macau. The deal, which includes upfront and milestone payments tied to sales and regulatory achievements, gives Osteopore access to the Chinese dental bone graft substitute and membrane market via Majeton and its parent Essex Bio-Technology Limited, whose extensive hospital network and sales infrastructure are expected to accelerate Osteopore’s regional expansion and reinforce its strategy of leveraging established partners to scale commercialisation and improve patient outcomes.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is an Australian-Singaporean regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The company focuses on innovative solutions for dental, orthodontic and maxillofacial surgery, and is pursuing broader applications in regenerative medicine across the Asia-Pacific region through partnerships with established healthcare and medtech distributors.
Average Trading Volume: 1,483,558
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$2.26M
For detailed information about OSX stock, go to TipRanks’ Stock Analysis page.